20.500.12556/RUL-176178 A common symptom geometry of mood improvement under sertraline and placebo associated with distinct neural patterns Background: Understanding the mechanisms of major depressive disorder (MDD) improvement is a key challenge to determining effective personalized treatments. Methods: To identify a data-driven pattern of clinical improvement in MDD and to quantify neural-to-symptom relationships according to antidepressant treatment, we performed a secondary analysis of the publicly available dataset EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care). In EMBARC, participants with MDD were treated either by sertraline or placebo for 8 weeks (Stage 1), and then switched to bupropion according to clinical response (Stage 2). We computed a univariate measure of clinical improvement through a principal component (PC) analysis on the variations of individual items of four clinical scales measuring depression, anxiety, suicidal ideas, and manic-like symptoms. We then investigated how initial clinical and neural factors predicted this measure during Stage 1 by running a linear model for each brain parcel’s resting-state global brain connectivity (GBC) with individual improvement scores during Stage 1. Results: The first PC (PC1) was similar across treatment groups at stages 1 and 2, suggesting a shared pattern of symptom improvement. PC1 patients’ scores significantly differed according to treatment, whereas no difference in response was evidenced between groups with the Clinical Global Impressions Scale. Baseline GBC correlated with Stage 1 PC1 scores in the sertraline but not in the placebo group. Using data-driven reduction of symptom scales, we identified a common profile of symptom improvement with distinct intensity between sertraline and placebo. Conclusions: Mapping from data-driven symptom improvement onto neural circuits revealed treatment-responsive neural profiles that may aid in optimal patient selection for future trials. data reduction functional neuroimaging mood spectrum statistical learning symptoms mapping personalized patient selection data processing neuroimaging emotional states personalized medicine obdelava podatkov slikanje možganov čustvena stanja statistično učenje personalizirana medicina true false true Angleški jezik Slovenski jezik Članek v reviji 2025-11-24 10:16:44 2025-11-24 10:16:53 2025-12-18 04:09:04 0000-00-00 00:00:00 2025 0 0 14 str. art. e185 Vol. 55 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.8:616.895.4 1469-8978 10.1017/S0033291725100962 258349315 Matkovic_A_common_symptom_geometry_of_mood_improvement_under_sertraline_and_placebo_associated_with_distinct_neural_patterns.pdf Matkovic_A_common_symptom_geometry_of_mood_improvement_under_sertraline_and_placebo_associated_with_distinct_neural_patterns.pdf 1 A2D0D8558CC32AAD3D1CAFCE44C5490C 42450cc992d2cd7e4704279ecea0fbfd6c466ff3c6c90275a30c493d14c1fbb3 4974f828-c916-11f0-9328-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=222419 https://www.cambridge.org/core/journals/psychological-medicine/article/common-symptom-geometry-of-mood-improvement-under-sertraline-and-placebo-associated-with-distinct-neural-patterns/BAA1B2C30EFA60408D8C7CD634815956 1 f7bde623-c915-11f0-9328-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=222418 Filozofska fakulteta 0 0 0